Breaking Down Immunome, Inc. (IMNM) Financial Health: Key Insights for Investors

Are you keeping a close watch on Immunome, Inc. (IMNM) and trying to understand its financial standing? As of December 31, 2024, Immunome reported a solid cash position of $217.3 million, further boosted by $172.5 million from financing in January 2025. But how does this cash balance stack up against their expenses, considering they reported a net loss of $293.0 million for 2024? With R&D expenses at $129.5 million, in-process R&D at $152.3 million, and G&A expenses at $33.0 million for 2024, can Immunome maintain its financial health while advancing its drug pipeline, including the Phase 3 trial for varegacestat and the Phase 1 trial for IM-1021?

Immunome, Inc. (IMNM) Revenue Analysis

Understanding Immunome, Inc.'s revenue streams is crucial for investors. A comprehensive analysis reveals the sources, growth, and changes in the company's revenue.

In 2024, Immunome, Inc. reported an annual revenue of $9.04 million, marking a -35.50% decrease compared to the previous year. Examining Immunome, Inc.'s financial health, it's important to consider that revenue, also known as sales, represents the income a company generates from its business activities, such as selling products or services. It differs from profit because it doesn't account for any expenses.

For a deeper understanding of Immunome, Inc.'s financial positioning, explore the Mission Statement, Vision, & Core Values of Immunome, Inc. (IMNM).

While specific details on Immunome, Inc.'s primary revenue sources, contribution of different business segments, and regional breakdown for 2024 are not available in the provided search results, some historical data and broader context can be pieced together. For example, in the third quarter of 2024, Immunome's research and development expenses were $37.2 million, and general and administrative expenses totaled $9.5 million, resulting in a net loss of $47.1 million for the quarter.

Here's a look at Immunome, Inc.'s revenue picture:

• 2024 Revenue: $9.04 million
• Year-over-year Change: -35.50% decrease

While comprehensive details on specific revenue streams for 2024 are limited in the provided search results, it's worth noting that Immunome is a biotechnology company focused on developing targeted oncology therapies. The company's pipeline includes programs like Varegacestat, IM-1021, and IM-3050, with key milestones expected in the near future.

Immunome, Inc. (IMNM) Profitability Metrics

Assessing Immunome, Inc.'s (IMNM) financial health involves a detailed examination of its profitability metrics. Profitability, in simple terms, is the capacity to make a profit. Here’s an overview that will cover gross profit, operating profit, and net profit margins, alongside trends, comparisons, and operational efficiency.

As of the fiscal year 2024, Immunome, Inc. presents a complex financial landscape, especially when considering standard profitability measures. It is crucial to note that as a biotechnology company focused on research and development, Immunome's profitability metrics often reflect significant investments in these activities, which can result in negative profitability figures in the short term.

Here's a breakdown:

• Gross Profit: Immunome's gross profit is influenced by its revenue streams, primarily collaboration agreements and licensing.
• Operating Profit: This metric is vital as it illustrates the profitability of Immunome's core business operations, excluding interest and taxes. The operating profit is calculated by deducting operating expenses, such as research and development (R&D) and selling, general, and administrative (SG&A) expenses, from the gross profit.
• Net Profit Margins: The net profit margin represents the percentage of revenue that remains as net income after all expenses, including interest and taxes, have been deducted.

Given the nature of Immunome's operations, a comparison of profitability ratios with industry averages should be approached cautiously. The biotechnology industry often sees companies with negative profitability for extended periods, especially during intensive R&D phases. Investors typically focus on the potential of the drug pipeline and the company's ability to secure funding to sustain operations.

Analysis of operational efficiency for Immunome, Inc. primarily revolves around its cost management in R&D and SG&A activities. Efficient cost management is crucial for extending the company's cash runway and maximizing the return on investment in its drug development programs. Gross margin trends are less relevant for Immunome at its current stage, as revenue is not the primary driver of its financial performance.

For more detailed insights, you can explore: Breaking Down Immunome, Inc. (IMNM) Financial Health: Key Insights for Investors

Immunome, Inc. (IMNM) Debt vs. Equity Structure

Understanding how Immunome, Inc. (IMNM) finances its operations and growth is crucial for investors. This involves analyzing the company's debt levels, its debt-to-equity ratio, and how it strategically uses debt and equity financing.

As of the fiscal year 2024, Immunome, Inc. (IMNM) reported having a significant amount of debt. It's important to distinguish between the types of debt the company holds:

• Long-term debt: This includes obligations due beyond one year, often used to finance significant capital expenditures or long-term projects.
• Short-term debt: Consisting of obligations due within a year, this may include items like accounts payable, accrued expenses, and the current portion of long-term debt.

While specific figures for the fiscal year 2024 are essential for a precise analysis, examining previous trends can provide insight. For example, reviewing Immunome, Inc.'s financial statements from recent years would show how these debt levels have evolved and their impact on the company's financial stability. It is crucial to refer to the most recent filings with the Securities and Exchange Commission (SEC) to get the most accurate and up-to-date information.

The debt-to-equity ratio is a vital metric in assessing Immunome, Inc.'s financial leverage. It indicates the proportion of debt and equity the company uses to finance its assets. The formula is:

Debt-to-Equity Ratio = Total Liabilities / Shareholder's Equity

A high ratio suggests the company relies more on debt, which can increase financial risk. A lower ratio indicates a greater reliance on equity, which is generally considered less risky. Comparing Immunome, Inc.'s ratio to industry peers provides context. If the company's ratio is significantly higher than its peers, it may signal higher financial risk. Conversely, a much lower ratio might indicate a more conservative financial strategy.

Recent activities, such as new debt issuances, changes in credit ratings, or refinancing efforts, can significantly impact Immunome, Inc.'s financial structure. For example, securing a new line of credit can provide additional financial flexibility, while a credit rating downgrade may increase borrowing costs. Refinancing existing debt at a lower interest rate can improve cash flow and reduce overall debt burden.

Balancing debt and equity is a strategic decision. Debt financing can provide capital without diluting ownership, and the interest payments are tax-deductible, reducing the overall cost of borrowing. However, high debt levels can lead to financial distress if the company struggles to meet its obligations.

Equity financing, on the other hand, doesn't require repayment and can provide a buffer during downturns. However, it dilutes existing shareholders' ownership and earnings per share.

Immunome, Inc.'s approach to balancing debt and equity should align with its growth strategy, risk tolerance, and market conditions. Investors should monitor these factors closely to assess the company's financial health and long-term sustainability. Additional insights into the company's strategic vision can be found at: Mission Statement, Vision, & Core Values of Immunome, Inc. (IMNM).

Immunome, Inc. (IMNM) Liquidity and Solvency

Liquidity and solvency are critical indicators of a company's financial health, revealing its ability to meet short-term obligations and sustain long-term operations. For Immunome, Inc. (IMNM), assessing these metrics provides valuable insights into its financial stability and risk profile.

Here's an overview of Immunome, Inc.'s liquidity based on available information:

Current and Quick Ratios: These ratios measure a company's ability to cover its short-term liabilities with its short-term assets. A higher ratio generally indicates better liquidity.

• Current Ratio: The current ratio is calculated by dividing current assets by current liabilities.
• Quick Ratio: The quick ratio, also known as the acid-test ratio, excludes inventory from current assets, providing a more conservative measure of liquidity.

Analysis of Working Capital Trends: Working capital, defined as current assets minus current liabilities, indicates a company's operational liquidity. Monitoring trends in working capital can reveal whether a company's ability to meet its short-term obligations is improving or deteriorating.

Cash Flow Statements Overview: Analyzing cash flow statements provides insights into how Immunome, Inc. (IMNM) generates and uses cash. Key areas to examine include:

• Operating Cash Flow: Cash generated from the company's core business activities.
• Investing Cash Flow: Cash used for investments in assets, such as property, plant, and equipment.
• Financing Cash Flow: Cash flow related to debt, equity, and dividends.

Potential Liquidity Concerns or Strengths: Based on the analysis of these metrics, it's important to identify any potential liquidity concerns or strengths. For example:

• A declining current ratio or quick ratio may indicate potential liquidity issues.
• Strong operating cash flow and a positive working capital trend suggest healthy liquidity.

For further information, see: Breaking Down Immunome, Inc. (IMNM) Financial Health: Key Insights for Investors

Immunome, Inc. (IMNM) Valuation Analysis

Determining whether Immunome, Inc. (IMNM) is overvalued or undervalued requires a multifaceted approach, incorporating key financial ratios, stock performance analysis, and analyst sentiment. Let's delve into these aspects to provide a clearer picture for investors. For further insights into the company's direction, see Mission Statement, Vision, & Core Values of Immunome, Inc. (IMNM).

When evaluating Immunome, Inc. (IMNM), several key financial ratios come into play:

• Price-to-Earnings (P/E) Ratio: Given that Immunome, Inc. (IMNM) currently has negative earnings, the P/E ratio is not meaningful for valuation purposes. This is because the P/E ratio is calculated by dividing a company's stock price by its earnings per share (EPS), and negative earnings result in a negative or undefined P/E ratio, which cannot be used to assess valuation.
• Price-to-Book (P/B) Ratio: As of November 10, 2023, Immunome, Inc. (IMNM)'s Price to Book ratio is 1.78. This ratio compares a company's market capitalization to its book value of equity. A lower P/B ratio might suggest undervaluation, but it should be considered in conjunction with other factors.
• Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: Similar to the P/E ratio, if Immunome, Inc. (IMNM) has negative EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), the EV/EBITDA ratio is not particularly useful. A negative EBITDA would result in a negative or undefined EV/EBITDA ratio, making it difficult to draw meaningful conclusions about the company's valuation using this metric.

Analyzing Immunome, Inc.'s (IMNM) stock price trends can provide insights into market sentiment and investor confidence. Recent data indicates the following:

As of April 18, 2024, the stock closed at $6.11. Monitoring these fluctuations helps in understanding the stock's volatility and potential investment opportunities.

Currently, Immunome, Inc. (IMNM) does not offer a dividend yield, as it is not distributing dividends. Therefore, dividend payout ratios are not applicable.

Analyst consensus plays a crucial role in gauging market sentiment toward Immunome, Inc. (IMNM). According to the recent analyst ratings, the consensus is to Buy. Of 5 analysts, 1 gave a strong buy rating, 3 gave a buy rating, and 1 gave a hold rating. These ratings provide a summarized view of expert opinions on the stock's potential.

Immunome, Inc. (IMNM) Risk Factors

Immunome, Inc. (IMNM) faces a variety of internal and external risks that could significantly impact its financial health. These risks span industry competition, regulatory changes, market conditions, and specific operational and strategic challenges highlighted in their financial reports.

One of the primary risks Immunome faces is the intense competition within the biotechnology industry. The development and marketing of novel antibody-based therapies is highly competitive, with numerous companies, including large pharmaceutical firms and specialized biotech companies, vying for market share. This competitive landscape can lead to:

• Increased R&D costs: To maintain a competitive edge, Immunome must invest heavily in research and development, which can strain financial resources.
• Pricing pressures: The presence of competing therapies may force Immunome to lower prices, affecting revenue and profitability.
• Market access challenges: Securing favorable reimbursement and formulary placement for new therapies can be difficult due to competition.

Regulatory changes also pose a significant risk. The development and commercialization of Immunome's therapies are subject to extensive regulation by agencies such as the FDA in the United States and similar bodies in other countries. Changes in these regulations can impact:

• Clinical trial requirements: More stringent requirements for clinical trials can increase the time and cost of development.
• Approval pathways: Changes in approval processes can delay or prevent the market entry of new therapies.
• Post-market surveillance: Increased scrutiny of marketed products can lead to additional costs and potential liabilities.

Market conditions, including economic downturns and shifts in investor sentiment, can also affect Immunome's financial health. These conditions can impact:

• Access to capital: Economic uncertainty can make it more difficult and expensive to raise capital through equity or debt financing.
• Investor confidence: Negative market sentiment can lead to a decline in Immunome's stock price, affecting its ability to attract and retain investors.
• Partnering opportunities: Economic downturns can reduce the willingness of potential partners to invest in or collaborate on Immunome's programs.

Immunome's financial filings and earnings reports highlight several operational, financial, and strategic risks. These include:

• Reliance on key collaborations: Immunome depends on collaborations with other companies and institutions for the development and commercialization of its therapies. The failure of these collaborations could adversely affect its prospects.
• Clinical trial risks: The success of Immunome's clinical trials is uncertain, and delays or failures could significantly impact its pipeline and financial condition.
• Intellectual property protection: Immunome's success depends on its ability to protect its intellectual property, and challenges to its patents or other intellectual property rights could harm its competitive position.

While specific mitigation strategies are not always detailed in public filings, Immunome likely employs several common risk management practices, such as:

• Diversifying its pipeline: To reduce reliance on any single program, Immunome may pursue multiple therapeutic candidates across different indications.
• Securing strategic partnerships: Collaborations with larger pharmaceutical companies can provide financial support and expertise.
• Maintaining strong intellectual property protection: Immunome likely invests in securing and defending its patents and other intellectual property rights.
• Implementing robust clinical trial protocols: To ensure the integrity and validity of clinical trial data, Immunome likely adheres to rigorous protocols and quality control measures.

Immunome's latest 10-K filing, for the fiscal year ended December 31, 2024, outlines various risk factors that could affect the company's future performance. These risks are categorized into several key areas:

Understanding these risks is crucial for investors assessing Immunome's long-term viability and investment potential. Comprehensive risk management and proactive mitigation strategies are essential for Immunome to navigate these challenges and achieve its strategic goals.

To gain more insight into investor behavior and company performance, check out this related article: Exploring Immunome, Inc. (IMNM) Investor Profile: Who’s Buying and Why?

Immunome, Inc. (IMNM) Growth Opportunities

Immunome, Inc. (IMNM) is focusing on discovering and developing first-in-class and best-in-class antibody therapeutics to treat cancer. Their approach involves:

• Unlocking Novel Targets: Identifying previously unexplored cancer targets.
• Generating Therapeutic Antibodies: Creating antibodies designed to bind to these novel targets.
• Developing into Therapeutics: Advancing these antibodies into clinical-stage therapeutics.

Here's a breakdown of Immunome's potential growth drivers, revenue projections, strategic initiatives, and competitive advantages:

Key Growth Drivers:

• Product Innovation: Immunome's primary growth driver is its innovative approach to discovering and developing novel antibody therapeutics. This includes identifying new cancer targets and creating antibodies that can effectively bind to these targets.
• Market Expansion: While specific details on market expansion strategies are not available in the provided context, potential growth could come from expanding the indications for their existing pipeline or targeting new geographical markets.

Future Revenue Growth Projections and Earnings Estimates:

As of the fiscal year 2024, Immunome reported total revenue of $2.1 million. This revenue was primarily derived from the research collaboration with AbbVie. The company's net loss for the year was $65.7 million, reflecting significant investment in research and development activities. Future revenue growth is highly dependent on the successful development and commercialization of their antibody therapeutics.

Strategic Initiatives or Partnerships:

Immunome's collaboration with AbbVie is a key strategic initiative. This research collaboration focuses on:

• Novel Target Identification: Working together to discover new targets for cancer therapy.
• Antibody Development: Developing antibodies that can bind to these novel targets.

This partnership not only provides revenue but also validates Immunome's technology and approach. Additional partnerships and collaborations could further drive growth and provide financial resources.

Competitive Advantages:

Immunome's competitive advantages stem from its unique approach to antibody discovery and development:

• Novel Target Identification: Immunome focuses on identifying previously unexplored cancer targets, potentially leading to first-in-class therapeutics.
• Proprietary Technology Platform: The company's technology platform allows for the efficient discovery and development of antibodies against these novel targets.

These advantages could position Immunome to develop innovative cancer therapies and capture a significant share of the market.

For more detailed insights into Immunome, Inc.'s financial health, you can refer to this comprehensive analysis: Breaking Down Immunome, Inc. (IMNM) Financial Health: Key Insights for Investors